Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer

Sakuma,Kaori; Kurosumi,Masafumi; Oba,Hanako; Kobayashi,Yasuhito; Takei,Hiroyuki; Inoue,Kenichi; Tabei,Toshio; Oyama,Tetsunari

doi:10.3892/etm.2011.212

Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer

Authors:
- Kaori Sakuma
- Masafumi Kurosumi
- Hanako Oba
- Yasuhito Kobayashi
- Hiroyuki Takei
- Kenichi Inoue
- Toshio Tabei
- Tetsunari Oyama
View Affiliations

Affiliations: Department of Pathology, Saitama Cancer Center, Saitama 362-0806, Japan, Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan, Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan, Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Gunma, Japan
Published online on: January 20, 2011 https://doi.org/10.3892/etm.2011.212
Pages: 257-264

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although triple-negative breast cancer (TNBC) is associated with a poor prognosis, recent reports have indicated that a higher proportion of TNBC patients shows a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) than is the case for non-TNBC patients. The aim of this study was to identify markers that predict pCR to NAC in TNBC patients, and to clarify prognostic factors that affect the outcome of TNBC patients with residual disease (RD) after NAC. Among 44 TNBC patients who received anthracycline- and taxane-based combination NAC, we analyzed the relationship between pathological response and clinicopathological characteristics, including immunohistochemical parameters (cytokeratin 5/6, epidermal growth factor receptor, Ki-67, p53, breast cancer susceptibility protein 1 and topoisomerase IIα). We also assessed the prognostic impact on patients with RD by analyzing the correlation between disease-free survival (DFS) and clinicopathological parameters. Sixteen patients (36%) achieved a pCR and log-rank test showed that these patients had a significantly more favorable outcome than patients with RD (DFS, P=0.00184; overall survival, P=0.0080). Among the clinicopathological parameters examined, none was correlated with pathological response, with the exception of p53. Patients with immunohistochemical overexpression of p53 more frequently achieved a pCR than those without p53 overexpression (P=0.0484). In the patients with RD, the Cox proportional hazards model showed that the presence of lymphovascular invasion was significantly associated with shorter DFS (hazard ratio, 13.333; 95% CI 1.587-111.111; P=0.0171). p53 overexpression may be a key predictor of a favorable response to NAC. Since patients with RD, particularly those positive for lymphovascular invasion, had an extremely poor outcome, novel therapeutic approaches for these patients are warranted.

View Figures

View References

1.	Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M and Reis-Filho JS: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 111:27–44. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar
5.	Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
10.	Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Keam B, Im SA, Kim HJ, et al: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 7:2032007. View Article : Google Scholar
13.	Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN and Pusztai L: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 25:2650–2655. 2007. View Article : Google Scholar
14.	Tavassoli FA and Devilee P; World Health Organization: Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press; Lyon: 2003
15.	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
16.	Kurosumi M: Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer. 13:254–259. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE and Ellis IO: Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 18:26–35. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT and Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 19:264–271. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Kono S, Kurosumi M, Simooka H, Kawanowa K, Ninomiya J, Takei H, Suemasu K and Kuroda Y: Immunohistochemical study of the relationship between Ki-67 labeling index of proliferating cells of gynecomastia, histological phase and duration of disease. Pathol Int. 56:655–658. 2006. View Article : Google Scholar
20.	Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Tamaki T, Umemura T and Kakudo K: Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer. 92:54–60. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Dômont J, Spielmann M, Delaloge S, André F and Penault Llorca F: p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol. 19:1261–1265. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Børresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505–2512. 2001.PubMed/NCBI
23.	Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA and Lønning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 2:811–814. 1996. View Article : Google Scholar : PubMed/NCBI
24.	Mieog JS, van der Hage JA, van de Vijuer MJ and van de Velde CJ; Cooperating Investigators of the EORTC: Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. Eur J Cancer. 42:1369–1379. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Colleoni M, Orvieto E, Nolé F, et al: Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer. 35:574–579. 1999. View Article : Google Scholar : PubMed/NCBI
26.	Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A and de Thé H: Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. 4:e902007. View Article : Google Scholar : PubMed/NCBI
27.	Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y and Osamura RY: Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep. 14:337–343. 2005.
28.	Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fukushima H and Uchida K: EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep. 21:413–417. 2009.PubMed/NCBI
29.	Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J and Bergh J: Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 24:2428–2436. 2006. View Article : Google Scholar
30.	Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M and Reis-Filho JS: Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 106:181–189. 2007. View Article : Google Scholar : PubMed/NCBI
31.	MacGrogan G, Rudolph P, Mascarel Id I, et al: DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer. 89:666–671. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S and Isola J: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 156:839–847. 2000.PubMed/NCBI
33.	Lynch BJ, Guinee DG Jr and Holden JA: Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol. 28:1180–1188. 1997. View Article : Google Scholar : PubMed/NCBI
34.	Järvinen TA, Kononen J, Pelto-Huikko M and Isola J: Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol. 148:2073–2082. 1996.PubMed/NCBI